Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47778
Title: | Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency? | Authors: | Erbaş, İbrahim Mert Altıncık, Selda Ayça Çatlı, Gönül Ünüvar, Tolga Özhan, Bayram Abacı, Ahmet Anik A. |
Keywords: | Magnesium Magnesuria Mineralocorticoids Pediatrics Primary adrenal insufficiency aldosterone alkaline phosphatase calcium chloride corticotropin creatinine fludrocortisone magnesium parathyroid hormone phosphorus potassium renin thyrotropin vitamin D fludrocortisone magnesium mineralocorticoid adolescent adrenal insufficiency adult Article child clinical article congenital adrenal hyperplasia drug megadose female human hypomagnesemia infant male plasma renin activity retrospective study salt wasting urinalysis blood clinical trial congenital adrenal hyperplasia drug effect drug monitoring ion transport magnesium deficiency multicenter study procedures risk assessment treatment outcome urinary excretion urine Adrenal Hyperplasia, Congenital Child Drug Monitoring Female Fludrocortisone Humans Ion Transport Magnesium Magnesium Deficiency Male Mineralocorticoids Renal Elimination Retrospective Studies Risk Assessment Treatment Outcome |
Publisher: | Turkiye Klinikleri | Abstract: | Background/aim: Aldosterone is a mineralocorticoid that secreted from adrenal glands and a known factor to increase magnesium excretion by direct and indirect effects on renal tubular cells. Although the frequency of hypomagnesemia was found to be approximately 5% in adult studies, there is no study in the literature investigating the frequency of hypomagnesemia in children by using fludrocortisone, which has a mineralocorticoid activity. Materials and methods: A multi-center retrospective study was conducted, including children who were under fludrocortisone treatment for primary adrenal insufficiency and applied to participant pediatric endocrinology outpatient clinics. Results: Forty-three patients (58.1% male, 41.9% prepubertal) included in the study, whose median age was 9.18 (0.61-19) years, and the most common diagnosis among the patients was a salt-wasting form of congenital adrenal hyperplasia (67.4%). Mean serum magnesium level was 2.05 (±0.13) mg/dL, and hypomagnesemia was not observed in any of the patients treated with fludrocortisone. None of the patients had increased urinary excretion of magnesium. Conclusion: Unlike the studies performed in adults, we could not find any evidence of magnesium wasting effect of fludrocortisone treatment with normal or even high doses in children and adolescents. © TÜBİTAK. | URI: | https://doi.org/10.3906/sag-2008-167 https://search.trdizin.gov.tr/yayin/detay/485212 https://hdl.handle.net/11499/47778 |
ISSN: | 1300-0144 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
turkjmedsci-51-231.pdf | 131.14 kB | Adobe PDF | View/Open |
CORE Recommender
Page view(s)
72
checked on Aug 24, 2024
Download(s)
26
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.